0001564590-21-025066.txt : 20210506 0001564590-21-025066.hdr.sgml : 20210506 20210506164010 ACCESSION NUMBER: 0001564590-21-025066 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20210506 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210506 DATE AS OF CHANGE: 20210506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Oncternal Therapeutics, Inc. CENTRAL INDEX KEY: 0001260990 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 621715807 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50549 FILM NUMBER: 21898530 BUSINESS ADDRESS: STREET 1: 12230 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 434-1113 MAIL ADDRESS: STREET 1: 12230 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: GTX INC /DE/ DATE OF NAME CHANGE: 20030822 8-K 1 onct-8k_20210506.htm 8-K onct-8k_20210506.htm
false 0001260990 0001260990 2021-05-06 2021-05-06

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported) May 6, 2021

Oncternal Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

 

000-50549

 

62-1715807

(State or Other Jurisdiction
of Incorporation)

 

(Commission File
Number)

 

(IRS Employer Identification No.)

 

12230 El Camino Real

Suite 300
San Diego, CA 92130

(858) 434-1113

 

 

(Address and zip code; telephone number, including area code, of registrant’s principal executive offices)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ 

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐ 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

ONCT

 

The Nasdaq Stock Market, LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 2.02.Results of Operations and Financial Condition.

On May 6, 2021, Oncternal Therapeutics, Inc., issued a press release announcing its financial results for the first quarter ended March 31, 2021. A copy of this press release is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

Item 9.01.Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
No.

 

  

Description

 

 

 

99.1

 

  

Press Release, dated May 6, 2021

 

 

 

 

104

 

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

Oncternal Therapeutics, Inc.

 

 

 Date: May 6, 2021

By:

/s/ Richard G. Vincent

 

 

 

Name: Richard G. Vincent

 

 

 

Title: Chief Financial Officer

 

 

1

 

 EX-99.1 2 onct-ex991_6.htm EX-99.1 onct-ex991_6.htm

   Exhibit 99.1

 

Oncternal Provides Business Update and Announces First Quarter 2021 Financial Results

 

 

-

Interim results of a Phase 1b trial of cirmtuzumab and paclitaxel in locally advanced/unresectable or metastatic HER2-negative breast cancer compare favorably to historical single-agent paclitaxel data (57% ORR vs. ~30% ORR historical single-agent paclitaxel)

 

-

In a preclinical study of cirmtuzumab added to high-grade serous ovarian cancer cell lines, cirmtuzumab demonstrated single agent activity and enhanced the anti-proliferative effect of commonly used chemotherapies

 

-

Oncternal appointed Chase Leavitt as General Counsel

 

-

Oncternal presenting clinical updates on cirmtuzumab in MCL/CLL and TK216 in Ewing sarcoma at the ASCO Annual Meeting in June 2021

 

-

Management to host webcast today at 5:00 pm ET

SAN DIEGO, May 6, 2021 -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today reported financial results for the first quarter of 2021. Oncternal management will host a webcast today at 5:00 p.m. ET to discuss its first quarter of 2021 financial results and to provide a business update.

“We are continuing to advance our ROR1-focused platform in both liquid and solid tumors, while laying the groundwork for developing new ROR1 targeting cell therapies. Based on encouraging data recently reported at the American Association for Cancer Research (AACR) Annual Meeting, we are evaluating cirmtuzumab for other clinical development opportunities in solid tumors while continuing our FDA dialogue on a potential registration strategy in mantle cell lymphoma (MCL). In addition, we are supporting TK216, an ETS inhibitor which has generated encouraging results in Ewing sarcoma,” said James Breitmeyer, M.D., Ph.D., Oncternal’s President and CEO. “We also look forward to presenting several key clinical data at the American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held virtually from June 4-8, 2021.”

Recent Highlights

 

•

In April 2021, we presented two scientific posters at the AACR Annual Meeting, which showcased the promise of cirmtuzumab in treating solid tumors.

 

o

In a Phase 1b investigator-initiated clinical trial in heavily pre-treated patients with metastatic HER2-negative breast cancer treated with a combination of cirmtuzumab and paclitaxel, eight of 14 evaluable patients had a partial response (PR), one of which remained durable for 52 weeks, for an objective response rate (ORR) of 57%. Four additional patients (29%) had stable disease (SD). These results were consistent with the previously reported interim results of the study, and compared favorably to historical results for single-agent paclitaxel, particularly for patients such as these who had received a median of six prior therapies for metastatic disease. Cirmtuzumab when given with paclitaxel was well-tolerated and demonstrated no added toxicity over what was expected with paclitaxel alone. The trial is expected to enroll a total of 15 evaluable patients.

 

o

In a preclinical study of cirmtuzumab used to treat high-grade serous ovarian cancer (HGSOC) and endometrial cell lines in vitro alone or in combination with chemotherapeutic agents cisplatin and paclitaxel, cirmtuzumab demonstrated single agent activity and enhanced the anti-proliferative effects of chemotherapeutic agents in both ovarian and endometrial cancer cell models. Oncternal is currently evaluating next steps for cirmtuzumab in solid tumors including breast and ovarian cancer.

 

•

In April 2021, we appointed Chase Leavitt as General Counsel.

 

•

In April 2021, we announced that updated interim clinical trial results from Oncternal’s study of TK216 in patients with Ewing sarcoma will be presented in an oral session, and updated interim clinical trial results from Oncternal and UCSD’s study of cirmtuzumab plus ibrutinib in patients with MCL or chronic lymphocytic leukemia (CLL) will be presented in a poster session at the ASCO Annual Meeting in June 2021.

Expected Upcoming Milestones

 

•

Cirmtuzumab (ROR1 antibody) programs

 

o

Clinical data update for patients with MCL and CLL treated with cirmtuzumab plus ibrutinib in the ongoing Phase 1/2 study will be presented at the ASCO Annual Meeting

 

o

Preclinical data in additional ROR1-expressing tumors is expected to be available in the third quarter of 2021

 

•

ROR1 CAR-T program

 

o

First-in-human dosing is expected in the first half of 2022

 

 

 

 

•

TK216 (ETS inhibitor) program

 

o

Clinical data update for patients with Ewing sarcoma treated in the ongoing Phase 1/2 study will be presented at the ASCO Annual Meeting

 

o

Preclinical data in additional ETS-driven tumors is expected to be available in the third quarter of 2021

First Quarter 2021 Financial Results

Our grant revenue was $0.7 million for the first quarter ended March 31, 2021. Our grant revenue is derived from a sub-award under a grant from the California Institute for Regenerative Medicine (CIRM) to UC San Diego, which was awarded to advance our Phase 1/2 clinical trial evaluating cirmtuzumab in combination with ibrutinib for the treatment of patients with MCL or CLL.

Our total operating expenses for the first quarter ended March 31, 2021 were $6.7 million. Research and development expenses for the quarter totaled $3.9 million, and general and administrative expenses for the quarter totaled $2.8 million. Net loss for the first quarter was $5.9 million, or a loss of $0.12 per share, basic and diluted.

As of March 31, 2021, we had $111.2 million in cash and cash equivalents. We believe these funds will be sufficient to fund our operations into 2023. As of March 31, 2021, we had approximately 49.4 million shares of common stock outstanding.

Management Webcast

As previously announced, Oncternal will host a webcast today, May 6, 2021, at 5:00 p.m. ET (2:00 p.m. PT). The live webcast will be available online and may be accessed from the “Investors” page of the company website at http://investor.oncternal.com/. A replay of the webcast will be available beginning approximately one hour after the conclusion of the call and will remain available for at least 30 days thereafter.

About Oncternal Therapeutics

Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The clinical pipeline includes cirmtuzumab, an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer. The clinical pipeline also includes TK216, an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. In addition, Oncternal has a program utilizing the cirmtuzumab antibody backbone to develop a CAR-T therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. More information is available at https://oncternal.com/.

Forward-Looking Information

Oncternal cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on Oncternal’s current beliefs and expectations. Forward-looking statements include statements regarding Oncternal’s development programs, including the anticipated timing for announcing additional preclinical and clinical data; timing of reaching any milestones, including initiating ROR1 CAR-T studies; Oncternal’s evaluation of clinical development opportunities; and Oncternal’s expected cash runway. Forward-looking statements are subject to risks and uncertainties inherent in Oncternal’s business, including risks associated with the clinical development and process for obtaining regulatory approval of Oncternal’s product candidates, such as potential delays in the commencement, enrollment and completion of clinical trials; the risk that results seen in a case study of one patient likely will not predict the results seen in other patients in the clinical trial; the risk that interim results of a clinical trial do not predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, as follow-up on the outcome of any particular patient continues, and as more patient data become available; and other risks described in Oncternal’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Oncternal undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

 

 

 

 

Oncternal Contacts:

 

Company Contact

Richard Vincent

858-434-1113

rvincent@oncternal.com

 

Investor Contact

Corey Davis, Ph.D.

LifeSci Advisors

212-915-2577

cdavis@lifesciadvisors.com

 

 

 

Source: Oncternal Therapeutics


 

 

 

 

Oncternal Therapeutics, Inc.
Condensed Consolidated Balance Sheets Data
(in thousands)

 

 

 

 

March 31,

2021

 

 

 

December 31,

2020

 

Cash and cash equivalents

 

$

 

111,211

 

 

$

 

116,737

 

Total assets

 

 

 

114,057

 

 

 

 

118,809

 

Total liabilities

 

 

 

5,754

 

 

 

 

5,858

 

Accumulated deficit

 

 

 

(88,745

)

 

 

 

(82,797

)

Total stockholders' equity

 

 

 

108,303

 

 

 

 

112,951

 

 

Oncternal Therapeutics, Inc.
Condensed Consolidated Statements of Operations Data
(Unaudited; in thousands, except per share data)

 

 

 

Three Months Ended

March 31,

 

 

 

 

2021

 

 

 

2020

 

Grant revenue

 

$

 

748

 

 

$

 

578

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

 

3,913

 

 

 

 

2,696

 

General and administrative

 

 

 

2,794

 

 

 

 

2,633

 

Total operating expenses

 

 

 

6,707

 

 

 

 

5,329

 

Loss from operations

 

 

 

(5,959

)

 

 

 

(4,751

)

Interest income

 

 

 

11

 

 

 

 

13

 

Net loss

 

$

 

(5,948

)

 

$

 

(4,738

)

Net loss per share, basic and diluted

 

$

 

(0.12

)

 

$

 

(0.31

)

Weighted-average shares outstanding, basic and diluted

 

 

 

49,094

 

 

 

 

15,355

 

 

 

 GRAPHIC 3 ggs0rkpb4jd3000001.jpg GRAPHIC begin 644 ggs0rkpb4jd3000001.jpg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end GRAPHIC 4 ggs0rkpb4jd3000002.jpg GRAPHIC begin 644 ggs0rkpb4jd3000002.jpg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end EX-101.SCH 5 onct-20210506.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 6 onct-20210506_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation State Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 7 onct-20210506_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 onct-8k_20210506_htm.xml IDEA: XBRL DOCUMENT 0001260990 2021-05-06 2021-05-06 false 0001260990 8-K 2021-05-06 Oncternal Therapeutics, Inc. DE 000-50549 62-1715807 12230 El Camino Real Suite 300 San Diego CA 92130 (858) 434-1113 false false false false Common Stock, par value $0.001 per share ONCT NASDAQ false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document and Entity Information
May 06, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 06, 2021
Entity Registrant Name Oncternal Therapeutics, Inc.
Entity Central Index Key 0001260990
Entity Emerging Growth Company false
Entity File Number 000-50549
Entity Incorporation State Country Code DE
Entity Tax Identification Number 62-1715807
Entity Address, Address Line One 12230 El Camino Real
Entity Address, Address Line Two Suite 300
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92130
City Area Code (858)
Local Phone Number 434-1113
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol ONCT
Security Exchange Name NASDAQ
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.oncternal.com/20210506/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports onct-8k_20210506.htm onct-20210506.xsd onct-20210506_lab.xml onct-20210506_pre.xml onct-ex991_6.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "onct-8k_20210506.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "onct-8k_20210506.htm" ] }, "labelLink": { "local": [ "onct-20210506_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "onct-20210506_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "onct-20210506.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "onct", "nsuri": "http://www.oncternal.com/20210506", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "onct-8k_20210506.htm", "contextRef": "C_0001260990_20210506_20210506", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.oncternal.com/20210506/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "onct-8k_20210506.htm", "contextRef": "C_0001260990_20210506_20210506", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "verboseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oncternal.com/20210506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oncternal.com/20210506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oncternal.com/20210506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oncternal.com/20210506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oncternal.com/20210506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oncternal.com/20210506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oncternal.com/20210506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oncternal.com/20210506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oncternal.com/20210506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oncternal.com/20210506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oncternal.com/20210506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oncternal.com/20210506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oncternal.com/20210506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oncternal.com/20210506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oncternal.com/20210506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oncternal.com/20210506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oncternal.com/20210506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oncternal.com/20210506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oncternal.com/20210506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oncternal.com/20210506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oncternal.com/20210506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oncternal.com/20210506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.oncternal.com/20210506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001564590-21-025066-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-025066-xbrl.zip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end